China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7
38.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio pharmaceutical Group Co Ltd
Pre-Tax Income
China Resources Boya Bio pharmaceutical Group Co Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Pre-Tax Income
¥258.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
8%
|
|
|
Beigene Ltd
HKEX:6160
|
Pre-Tax Income
-¥6.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Pre-Tax Income
¥1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Pre-Tax Income
¥1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Pre-Tax Income
¥2.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Pre-Tax Income
¥4.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
39%
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Pre-Tax Income?
Pre-Tax Income
258.9m
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Pre-Tax Income amounts to 258.9m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
8%
Over the last year, the Pre-Tax Income growth was -57%. The average annual Pre-Tax Income growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been -16% over the past three years , -16% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
